The effectiveness of six months of donepezil in the treatment of cognitive deterioration in patients with alzheimer-type dementia;Efectividad a los seis meses del donepecilo en el tratamiento del deterioro cognitivo en pacientes con demencia tipo Alzheimer

Revista de Neurologia

Volumn 31, Issue 8, 2000, Pages 724-728

  Lopez Pousa S ^a  

^a Hospital de Santa Caterina   (Spain)

Author keywords

Alzheimer's disease; Anticholinesterases; Cognitive deterioration; Donepezil; Percentage variation index after six months

Indexed keywords

DONEPEZIL; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ARTICLE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; TIME;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; COGNITION DISORDERS; CONFIDENCE INTERVALS; FEMALE; HUMANS; INDANS; MALE; NOOTROPIC AGENTS; PIPERIDINES; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0034675443     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3108.2000316     Document Type: Article

References (3)

1. López-Pousa S, Lombardía-Fernández C. Tratamiento de la enfermedad de Alzheimer; fármacos inhibidores de la enzima acetilcolinesterasa. Neurologia 1999; 14; 180-8.
2. Rogers SL, Yamanishi Y, Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. In Becker R, Giacobini E, eds. Cho-linergic basis for Alzheimer therapy. Boston: Birkhäuser; 1991. p. 314-20.
3. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl) methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995; 18: 1145-7.